MX2014001065A - Formulaciones de (trimetoxifenilamino) pirimidilino nuevas. - Google Patents

Formulaciones de (trimetoxifenilamino) pirimidilino nuevas.

Info

Publication number
MX2014001065A
MX2014001065A MX2014001065A MX2014001065A MX2014001065A MX 2014001065 A MX2014001065 A MX 2014001065A MX 2014001065 A MX2014001065 A MX 2014001065A MX 2014001065 A MX2014001065 A MX 2014001065A MX 2014001065 A MX2014001065 A MX 2014001065A
Authority
MX
Mexico
Prior art keywords
trimethoxyphenylamino
pyrimidinyl
formulations
new
hydrate
Prior art date
Application number
MX2014001065A
Other languages
English (en)
Other versions
MX339685B (es
Inventor
Farhan Abdul Karim Alhusban
Ian Paul Gabbott
Bindhumadhavan Gururajan
Dawn Sievwright
David Bradley Brook Simpson
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46875902&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014001065(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of MX2014001065A publication Critical patent/MX2014001065A/es
Publication of MX339685B publication Critical patent/MX339685B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan composiciones farmacéuticas que comprenden mas de un 15% p/p del compuesto de Fórmula (I), según se define en la presente, y/o un hidrato de este y una cantidad de uno o mas agentes efervescentes que sea suficiente para proporcionar una disolución satisfactoria in vitro; y que comprenden además uno o más ingredientes farmacéuticamente aceptables; y procesos para obtenerlas.
MX2014001065A 2011-07-28 2012-07-26 Formulaciones de (trimetoxifenilamino) pirimidinilo nuevas. MX339685B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512621P 2011-07-28 2011-07-28
PCT/GB2012/051791 WO2013014454A1 (en) 2011-07-28 2012-07-26 New (trimethoxyphenylamino)pyrimidinyl formulations

Publications (2)

Publication Number Publication Date
MX2014001065A true MX2014001065A (es) 2014-08-01
MX339685B MX339685B (es) 2016-06-06

Family

ID=46875902

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001065A MX339685B (es) 2011-07-28 2012-07-26 Formulaciones de (trimetoxifenilamino) pirimidinilo nuevas.

Country Status (27)

Country Link
US (2) US8771648B2 (es)
EP (1) EP2736487B2 (es)
JP (1) JP6019116B2 (es)
KR (2) KR102090440B1 (es)
CN (1) CN103826610B (es)
AR (1) AR087371A1 (es)
AU (1) AU2012288632B2 (es)
BR (1) BR112014001999B1 (es)
CA (1) CA2843138C (es)
CY (1) CY1122596T1 (es)
DK (1) DK2736487T4 (es)
EA (1) EA028432B1 (es)
ES (1) ES2710423T5 (es)
FI (1) FI2736487T4 (es)
HR (1) HRP20190186T4 (es)
HU (1) HUE042611T2 (es)
LT (1) LT2736487T (es)
MX (1) MX339685B (es)
PL (1) PL2736487T5 (es)
PT (1) PT2736487T (es)
RS (1) RS58433B2 (es)
SI (1) SI2736487T2 (es)
SM (1) SMT201900071T1 (es)
TR (1) TR201901792T4 (es)
TW (1) TW201311251A (es)
UY (1) UY34223A (es)
WO (1) WO2013014454A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE540041T1 (de) * 2006-11-21 2012-01-15 Rigel Pharmaceuticals Inc Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon
HRP20190186T4 (hr) 2011-07-28 2024-12-20 Rigel Pharmaceuticals, Inc. Nove formulacije (trimetoksifenilamino)pirimidinila
PL3283551T3 (pl) 2015-04-02 2021-04-06 Stora Enso Oyj Kompozycja aktywowanej ligniny, sposób jej wytwarzania oraz jej zastosowanie
WO2016172053A1 (en) 2015-04-24 2016-10-27 Rigel Pharmaceuticals, Inc. Methods of treating ibrutinib-resistant disease
SE542795C2 (en) 2018-10-08 2020-07-07 Stora Enso Oyj Process for preparing a resin
DK4178548T3 (da) * 2020-07-07 2024-08-19 Celgene Corp Farmaceutiske sammensætninger omfattende (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUORBENZONITRIL
WO2022017864A1 (en) * 2020-07-24 2022-01-27 Dsm Ip Assets B.V. New fast dissolvable tablets

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2291433T3 (es) † 2002-03-04 2008-03-01 Orbus Pharma Inc. Composiciones de cefuroxima axetilo de liberacion rapida.
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
WO2005012294A1 (en) 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
ATE506953T1 (de) 2003-08-07 2011-05-15 Rigel Pharmaceuticals Inc 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
US20060051406A1 (en) * 2004-07-23 2006-03-09 Manjeet Parmar Formulation of insoluble small molecule therapeutics in lipid-based carriers
EP1794135A1 (en) * 2004-09-27 2007-06-13 Amgen Inc. Substituted heterocyclic compounds and methods of use
RU2361867C2 (ru) † 2004-11-23 2009-07-20 Донг Вха Фармасьютикал. Инд. Ко., Лтд. Диметансульфонат n-гидрокси-4{5-[4-(5-изопропил-2-метил-1, 3-тиазол-4-ил)фенокси]пентокси}бензамидина
AU2006206458B2 (en) * 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
CA2631875A1 (en) * 2005-12-06 2007-10-04 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
US7659280B2 (en) * 2006-02-17 2010-02-09 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
US20090048214A1 (en) * 2006-11-15 2009-02-19 Rigel Pharmaceuticals, Inc Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds
ATE540041T1 (de) * 2006-11-21 2012-01-15 Rigel Pharmaceuticals Inc Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon
WO2009003136A1 (en) * 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
US20090088371A1 (en) * 2007-08-28 2009-04-02 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
UA102825C2 (ru) * 2007-11-07 2013-08-27 Райджел Фармасьютикалз, Инк. Фармацевтическая композиция, полученная влажным гранулированием с использованием вещества, которое связывает воду
MX2010009159A (es) 2008-02-22 2010-09-14 Rigel Pharmaceuticals Inc Uso de 2,4-pirimidindiaminas para el tratamiento de aterosclerosis.
UA108077C2 (xx) * 2009-07-02 2015-03-25 Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
EP2454265A2 (en) 2009-07-17 2012-05-23 Rigel Pharmaceuticals, Inc. Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
JP5681723B2 (ja) 2009-11-20 2015-03-11 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用
CA2792278C (en) 2010-04-13 2019-05-14 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses
HRP20190186T4 (hr) † 2011-07-28 2024-12-20 Rigel Pharmaceuticals, Inc. Nove formulacije (trimetoksifenilamino)pirimidinila

Also Published As

Publication number Publication date
UY34223A (es) 2013-02-28
AU2012288632B2 (en) 2017-08-17
JP6019116B2 (ja) 2016-11-02
KR20140058576A (ko) 2014-05-14
JP2014521630A (ja) 2014-08-28
HRP20190186T1 (hr) 2019-03-22
EP2736487A1 (en) 2014-06-04
US8771648B2 (en) 2014-07-08
TR201901792T4 (tr) 2019-03-21
TW201311251A (zh) 2013-03-16
SMT201900071T1 (it) 2019-02-28
DK2736487T4 (da) 2024-11-04
US20130058876A1 (en) 2013-03-07
PL2736487T5 (pl) 2025-01-27
EP2736487B1 (en) 2018-11-07
CY1122596T1 (el) 2021-01-27
ES2710423T5 (en) 2025-02-13
FI2736487T4 (fi) 2024-10-31
KR102090440B1 (ko) 2020-03-17
KR102024120B1 (ko) 2019-09-23
EP2736487B2 (en) 2024-08-28
SI2736487T2 (sl) 2025-06-30
US8951504B2 (en) 2015-02-10
CN103826610B (zh) 2017-08-04
RS58433B1 (sr) 2019-04-30
CN103826610A (zh) 2014-05-28
ES2710423T3 (es) 2019-04-25
PL2736487T3 (pl) 2019-06-28
BR112014001999B1 (pt) 2023-11-28
HK1198741A1 (en) 2015-06-05
EA028432B1 (ru) 2017-11-30
HRP20190186T4 (hr) 2024-12-20
DK2736487T3 (en) 2019-03-04
MX339685B (es) 2016-06-06
RS58433B2 (sr) 2025-01-31
CA2843138A1 (en) 2013-01-31
KR20190109576A (ko) 2019-09-25
HUE042611T2 (hu) 2019-07-29
US20140271493A1 (en) 2014-09-18
WO2013014454A1 (en) 2013-01-31
BR112014001999A2 (pt) 2017-02-21
EA201490363A1 (ru) 2014-06-30
PT2736487T (pt) 2019-02-13
CA2843138C (en) 2020-06-02
LT2736487T (lt) 2019-02-25
AU2012288632A1 (en) 2014-02-20
AR087371A1 (es) 2014-03-19
SI2736487T1 (sl) 2019-04-30

Similar Documents

Publication Publication Date Title
MX339685B (es) Formulaciones de (trimetoxifenilamino) pirimidinilo nuevas.
MX2011010311A (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
MX348823B (es) Formulaciones estables de linaclotida.
MX363435B (es) Formulaciones topicas que tienen biodisponibilidad aumentada.
NZ708593A (en) Novel pyrazole derivative
MX2014000130A (es) Procedimientos y composiciones para la inhibicion de resorcion osea.
MX2010014234A (es) Compuestos pirazol 436.
CA2818187C (en) Bromodomain inhibitors and uses thereof
IN2014MN01754A (es)
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MA34055B1 (fr) Chlorhydrate d'agomelatine hydrate et sa preparation
MY174090A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
IN2014DN01619A (es)
PH12013500784A1 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
GEP20135997B (en) Tricyclic indazole compound, method of their preparation and pharmaceutical composition containing thereof
TW200833335A (en) New pyridine analogues
MX342859B (es) Polisacarido de las semillas de tamarindo para usarse en el tratamiento de enfermedades inflamatorias.
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
IN2014MN02156A (es)
TW200833333A (en) New pyridine analogues
EA032913B1 (ru) Препараты производных пиримидиндиона
MX2013012038A (es) Combinacion de carotenoide, fitoestrogeno y vitamina c para la humectacion de la piel.
PH12015501389A1 (en) Pharmaceutical formulation of n- [5-[2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl] benzamide
IN2014MN02433A (es)

Legal Events

Date Code Title Description
FG Grant or registration